Cost‐optimization in the treatment of multidrug resistant tuberculosis in Nigeria
- 18 December 2015
- journal article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 21 (2) , 176-182
Abstract
To compare the cost of facility-based MDR TB care (F) to home-based care (H) from the perspective of the Nigerian national health system.We assessed the expected costs of the two MDR TB treatment approaches using a decision-analytic model with a follow-up of 6 months. MDR TB treatment outcomes were obtained from a systematic review of randomized clinical trials. The outcomes of interest included treatment success, treatment failure, treatment default, and mortality, and did not vary significantly between the two alternatives. Treatment costs included the cost of: drug therapy (F, H), hospital stay (F), nurse care (F, H), physician care (F), nursing facility (F), and transport to the health care provider (H). Finally, we estimated the potential cost savings associated with home-based treatment for all patients starting MDR TB treatment in Nigeria.The average expected total treatment cost for a Nigerian patient treated for MDR TB was estimated at US$ 2095 for facility-based care and $ 1535 for home-based care, a potential saving of 25%. One of the major drivers of this difference is the significantly more intensive, and therefore more costly, nursing care in hospitals. In 2013, a total of 426 patients were initiated on facility-based MDR TB treatment in Nigeria. Thus the potential savings through home-based care are US$ 223,204 per year.In Nigeria, treatment of MDR TB using home-based care is expected to result in similar patient outcomes at markedly reduced public health costs as facility-based care. This article is protected by copyright. All rights reserved.
Keywords
This publication has 13 references indexed in Scilit:
- Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysisBMC Infectious Diseases, 2014
- Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007Emerging Infectious Diseases, 2014
- Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in NigeriaPLOS ONE, 2014
- A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant TuberculosisThe American Journal of Tropical Medicine and Hygiene, 2013
- Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness AnalysisPLOS ONE, 2012
- The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?The Lancet, 2012
- Extensively Drug-resistant Tuberculosis: Epidemiology and Management ChallengesInfectious Disease Clinics of North America, 2010
- Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern AfricaPLOS ONE, 2009
- Multidrug‐Resistant and Extensively Drug‐Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South AfricaThe Journal of Infectious Diseases, 2007
- Treatment of Multidrug‐Resistant Tuberculosis in San Francisco: An Outpatient‐Based ApproachClinical Infectious Diseases, 2005